ולטרקס טבליות 500 מג

País: Israel

Língua: hebraico

Origem: Ministry of Health

Compre agora

Ingredientes ativos:

VALACICLOVIR AS HYDROCHLORIDE

Disponível em:

GLAXO SMITH KLINE (ISRAEL) LTD

Código ATC:

J05AB11

Forma farmacêutica:

טבליות מצופות פילם

Composição:

VALACICLOVIR AS HYDROCHLORIDE 500 MG

Via de administração:

פומי

Tipo de prescrição:

מרשם נדרש

Fabricado por:

GLAXO WELLCOME SA, SPAIN

Grupo terapêutico:

VALACICLOVIR

Área terapêutica:

VALACICLOVIR

Indicações terapêuticas:

Valtrex is indicated for the treatment of herpes zoster (shingles) in immunocopotent adults.Valtrex accelerates the resolution of pain, it reduces the duration, and the proportion of patients with zoster-associated pain, which includes acute and post-herpetic neuralgia. The efficacy of valaciclovir in immunocompromised patients has not been established. Valtrex is indicated for the treatment of the initial and recurrent genital herpes due to herpes simplex infection. Valtrex is indicated for the prevention (suppression) of recurrent herpes simplex infections (herpes genitalis). Prophylaxis of cytomegalovirus infection and disease, following organ transplantation. For the treatment of cold sores (herpes labialis).

Resumo do produto:

התרופה תינתן למניעת מחלת CMV במושתלי איברים

Data de autorização:

2021-02-28

Folheto informativo - Bula

                                " (
)
-
1986
500
"
500
(
) "
VALACICLOVIR (AS HYDROCHLORIDE)
500
MG
6
.
.
.
,
.
.
.
.
1
.
?
)
HSV
) ,(
VZV
(
-
)
CMV
.(
:
•
.
•
VZV
)
ophthalmic zoster
(
.
•
)
HSV
(
)
(
.
.
•
)
HSV
. (
•
CMV
.
:
.
2
.
:
()
)
6
.(
: ,
•
.
•
.
•
65
.
•
.
-
:
)
DRESS
(
.
DRESS
,
. (
)
← ,
. , . , , .
. / , , , . ,
: .
,
,
, ,
. , , , , ,
.
,
,
,
.
.
)
.(
3
.
?
.
.
.
:
)
zoster
s
Herpe
(
•
1,000
)
"
500
,("
.
•
.
)
sores
Cold
)
(
12
(
•
2,000
) "
500
. ,("
•
12
)
6
. (
•
. (
)
HSV
)
12
(
•
500
. ,"
•
.
3
5
.
HSV
)
12
(
•
500
.
,"
•
.
CMV
)
-
)
(
12
(
•
2,000
) "
500
,("
.
•
6
.
•
.
•
90
,
.
:
•
65
.
•
.
•
.
←
.
.
:
•
.
•
.
•
.//
•
.
•
.
65
.
.
.
.
,
.
,
, , ,
. ,
,
,
,
.
, .
,
. ,
.
. ! .
.
. ,
4
.
,
.
. .
:
←
:
.
.(
)
:
•
,
•
()
, , ,
•
.
) ,
.
DRESS
(
. ,
:
)
COMMON
VERY
(
-
:
•
)
COMMON
(
-
-
10
-
1
100
:
•
•
•
•
•
(
)
•
•
)
UNCOMMON
(
-
-
10
-
1
1,000
:
•
•
()
•
•
•
,
,
,
-
8
.
.
:
•
()
•
•
, ,
(
)
•
( )
•
()
:
•
(
)
•
(
)
•
)
RE
RA
(
-
-
10
-
1
10,000
:
•
()
•
() ,
•
()
•
()
•
()
•
()
,
,
,
-
8
.
.
:
•
)
(
:
•
DRESS
,
,
,
,()
,
.
2
.
•
(tubulointerstitial nephritis) ,
. ,
"
"
)
www.health.gov.il
" ,
(
:
https://sideeffects.health.gov.il/
5
.
?
•
!
.
/
.
•
)
exp. date
(
.
.
•
-
C
30°
.
6
.
• ,
:
Microcrystalline cellulose
Crospovidone
Povidone ,K90
White Colour Concentrate YS-
18043
-
1
(Hypromellose, Titanium dioxide, Polysorbate 80, Polyethylene Glycol
400)
Magnesium stearate
Colloidal Anhydrous Silica
Carnauba wax.
•
:
.
500
"
2
,
10
42
.
-
"
GX CF1
"
.
.
•
:
S.A.
.
, ,
•
:
' ," (
)
25
. ,
•
:
100-39-28426-00
.
,
.
,
.
GSK
.
©
2023
GSK
.
2023
.
Val PT v9A
                                
                                Leia o documento completo
                                
                            

Documentos em outros idiomas

Folheto informativo - Bula Folheto informativo - Bula inglês 07-06-2023
Características técnicas Características técnicas inglês 04-04-2023
Folheto informativo - Bula Folheto informativo - Bula árabe 07-06-2023